Journal article
Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center study
Abstract
BACKGROUND: Clinical practice guidelines recommend ustekinumab as a first-line biological treatment option for moderately-to-severely active Crohn's disease (CD). However, there is limited real-world effectiveness and safety data in bio-naïve patients.
AIMS: To assess ustekinumab effectiveness and safety in bio-naïve CD patients.
Authors
Bessissow T; Narula N; Ma C; In TSH; Eberg M; Karra K; Jairath V; Consortium CIR
Journal
Digestive and Liver Disease, Vol. 56, No. 1, pp. 61–69
Publisher
Elsevier
Publication Date
January 2024
DOI
10.1016/j.dld.2023.08.042
ISSN
1590-8658